These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24390981)

  • 1. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
    Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ
    Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
    Koga-Yamakawa E; Dovedi SJ; Murata M; Matsui H; Leishman AJ; Bell J; Ferguson D; Heaton SP; Oki T; Tomizawa H; Bahl A; Takaku H; Wilkinson RW; Harada H
    Int J Cancer; 2013 Feb; 132(3):580-90. PubMed ID: 22733292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.
    Dovedi SJ; Adlard AL; Ota Y; Murata M; Sugaru E; Koga-Yamakawa E; Eguchi K; Hirose Y; Yamamoto S; Umehara H; Honeychurch J; Cheadle EJ; Hughes G; Jewsbury PJ; Wilkinson RW; Stratford IJ; Illidge TM
    Oncotarget; 2016 Mar; 7(13):17035-46. PubMed ID: 26959743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
    Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
    J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
    Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
    Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.
    Koga-Yamakawa E; Murata M; Dovedi SJ; Wilkinson RW; Ota Y; Umehara H; Sugaru E; Hirose Y; Harada H; Jewsbury PJ; Yamamoto S; Robinson DT; Li CJ
    Cancer Immunol Immunother; 2015 Oct; 64(10):1229-39. PubMed ID: 26091797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
    Dovedi SJ; Melis MH; Wilkinson RW; Adlard AL; Stratford IJ; Honeychurch J; Illidge TM
    Blood; 2013 Jan; 121(2):251-9. PubMed ID: 23086756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
    Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
    Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation.
    Ota Y; Inagaki R; Nagai Y; Hirose Y; Murata M; Yamamoto S
    BMC Immunol; 2024 Jul; 25(1):48. PubMed ID: 39054418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinoma.
    Lin G; Wang X; Yi W; Zhang C; Xu G; Zhu X; Cai Z; Liu Y; Diao Y; Lin MC; Jin G
    J Transl Med; 2015 May; 13():166. PubMed ID: 25990580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
    Schölch S; Rauber C; Tietz A; Rahbari NN; Bork U; Schmidt T; Kahlert C; Haberkorn U; Tomai MA; Lipson KE; Carretero R; Weitz J; Koch M; Huber PE
    Oncotarget; 2015 Mar; 6(7):4663-76. PubMed ID: 25609199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
    Hamm S; Rath S; Michel S; Baumgartner R
    J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
    Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
    Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
    Kim H; Khanna V; Kucaba TA; Zhang W; Sehgal D; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2020 Jun; 17(6):2109-2124. PubMed ID: 32383885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
    Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
    Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.
    Wang D; Precopio M; Lan T; Yu D; Tang JX; Kandimalla ER; Agrawal S
    Mol Cancer Ther; 2010 Jun; 9(6):1788-97. PubMed ID: 20515950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects.
    Ota Y; Nagai Y; Hirose Y; Hori S; Koga-Yamakawa E; Eguchi K; Sumida K; Murata M; Umehara H; Yamamoto S
    Front Immunol; 2023; 14():1055671. PubMed ID: 36793737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells.
    Hackstein H; Hagel N; Knoche A; Kranz S; Lohmeyer J; von Wulffen W; Kershaw O; Gruber AD; Bein G; Baal N
    PLoS One; 2012; 7(8):e43320. PubMed ID: 22927956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.